GRANULES Intraday Analysis...

GRANULES Share Price

Open 113.40 Change Price %
High 114.90 1 Day -0.25 -0.22
Low 112.30 1 Week 10.10 9.76
Close 113.60 1 Month -2.00 -1.73
Volume 1056219 1 Year -1.90 -1.65
52 Week High 151.00
52 Week Low 91.45
GRANULES Important Levels
Resistance 2 116.01
Resistance 1 115.02
Pivot 113.60
Support 1 112.18
Support 2 111.19
NSE INDIA Most Active Stocks
SUZLON 17.15 9.24%
FEDERALBNK 77.10 0.39%
JPASSOCIAT 10.25 0.49%
ESL 6.05 19.80%
ESL 6.05 19.80%
ESL 6.05 19.80%
ESL 6.05 19.80%
VISESHINFO 0.20 33.33%
IDEA 69.35 2.82%
TORNTPOWER 197.75 6.32%
More..
NSE INDIA Top Gainers Stocks
VKSPL 0.15 50.00%
VISESHINFO 0.20 33.33%
VIVIDHA 2.40 20.00%
ZUARI 337.60 19.99%
RUCHISOYA 24.05 19.95%
PREMIER 37.10 19.87%
ESL 6.05 19.80%
ESL 6.05 19.80%
ESL 6.05 19.80%
ESL 6.05 19.80%
More..
NSE INDIA Top Losers Stocks
AUSTRAL 0.35 -12.50%
NICCO 0.40 -11.11%
GOLDTECH 7.05 -7.24%
NHPC 27.80 -6.71%
ZENITHBIR 0.70 -6.67%
JIKIND 0.70 -6.67%
JAIHINDPRO 6.50 -6.47%
ITDC 279.50 -5.67%
JMA 181.55 -5.15%
MBLINFRA 56.10 -5.00%
More..

Granules India Limited (NSE: GRANULES)

GRANULES Technical Analysis 2
As on 19th Jan 2017 GRANULES Share Price closed @ 113.60 and we RECOMMEND Sell for LONG-TERM with Stoploss of 123.52 & Strong Buy for SHORT-TERM with Stoploss of 109.09 we also expect STOCK to react on Following IMPORTANT LEVELS.
GRANULES Target for January
1st Target up-side 117.23
2nd Target up-side 123.67
3rd Target up-side 130.11
1st Target down-side 98.87
2nd Target down-side 92.43
3rd Target down-side 85.99
GRANULES Synopsis Technicals View
50 Day EMA N/A (Short Term)
N/A
100 Day EMA N/A (Mid Term) N/A
200 Day EMA N/A (Long Term) N/A
MACD (12 26 9) N/A N/A
RSI (14) N/A N/A
MFI (14) N/A N/A
CCI (20) N/A N/A
WILLIAM %R (14) N/A N/A
ADX (14) N/A N/A
PSAR N/A N/A
10 Day Avg Volume N/A
GRANULES Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.granulesindia.com
GRANULES Address
GRANULES
My Home Hub
2nd Floor
Hyderabad, 500081
India
Phone: 91 40 6676 0000
Fax: 91 40 2311 5145
GRANULES Latest News
Granules India Ltd to de-list GDR in Luxembourg Stock Exchange   Equity Bulls   - 19th Mar 15
Granules India seeks delisting of GDRs   Hindu Business Line   - 17th Mar 15
US FDA inspects Granules India facility   Business Standard   - 16th Mar 15
Granules India Ltd Fixes Record Date for Stock Split   Equity Bulls   - 10th Mar 15
Granules India, Belgian firm Ajinomoto OmniChem open APIs facility   Business Standard   - 24th Feb 15
Granules India to raise Rs 250 cr via QIP: VVS Murthy   Economic Times   - 05th Feb 15
Granules India to raise Rs. 250 cr   Hindu Business Line   - 28th Jan 15
Granules India Limited   Moneycontrol.com   - 28th Jan 15
Granules India Ltd to consider quarterly results on Jan 28, 2015   Equity Bulls   - 01st Jan 15
Granules India looks at further expansion   Business Standard   - 28th Nov 13
Interactive Technical Analysis Chart Granules India Limited ( GRANULES NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Granules India Limited
GRANULES Business Profile
Granules India is in the Pharmaceuticals sector. Granules’ predecessor company, a partnership called Umbrella Laboratories, was established in 1984, and the company is based in Hyderabad, India. The Company manufactures Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) which are distributed in over 50 countries. Granules manufactures several off-patent drugs, including Paracetamol, Ibuprofen, Metformin and Guaifenesin, on a large scale for customers in the regulated and semi-regulated markets. In 2008, Granules commenced operations at its finished dosage block at Gagillapur. The new block has enabled Granules to provide products throughout the pharmaceutical value chain to customers. The state-of-the-art facility has an annual capacity of 6 billion tablets per year and is scalable up to 12 billion tablets per year. The third piece of the business is the API division. Granules manufactures APIs for several drugs including Paracetamol, Ibuprofen, Metformin and Guaifenesin through 3 facilities. The current market capitalisation stands at Rs 333.94 crore.The company has reported a consolidated sales of Rs 266.05 crore and a Net Profit of Rs 15.11 crore for the quarter ended Sep 2013. The company management includes C Nageswara Rao - Chairman, C Krishna Prasad - Managing Director, L S Sarma - Director, A P Kurian - Director, C Parthasarathy - Director, Krishna Murthy Ella - Director, Arun Rao Akinepally - Director, Harsha Chigurupati - Executive Director, Uma Chigurupati - Executive Director, K B Sankara Rao - Additional Director. It is listed on the BSE with a BSE Code of 532482 and the NSE with an NSE Code of GRANULES. Its Registered office is at 2nd Floor, 3rd Block,,My Home Hub, Hyderabad,Andhra Pradesh - 500081.